A Phase I, Open-label Single Dose Escalating Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Nemolizumab in Pediatric Patients With Atopic Dermatitis
Phase 1
Completed
- Conditions
- Atopic dermatitis with pruritus who are inadequately controlled by existing therapies
- Registration Number
- JPRN-jRCT2080223685
- Lead Sponsor
- Maruho Co.,Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
Atopic Dermatitis with moderate or severe pruritus
Exclusion Criteria
1. Patients with Hepatitis B virus or hepatitis C virus infection
2. Patients with Evidence of tuberculosis (TB) infection
3. Patients with moderate or severe asthema symptoms
4. Patients with immune deficiency
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method